Yiğit, S.Aydin, T.Eyerci, N.Yayla, M.Duysak, L.Kaci, F.Ali Bingol, S.2026-03-262026-03-2620252405-844010.1016/j.heliyon.2025.e434912-s2.0-105008107877https://doi.org/10.1016/j.heliyon.2025.e43491https://hdl.handle.net/20.500.14901/3707Aim: In this study, we investigated how Jervine affected gastric tissue in rats following the development of indomethacin-induced ulcers. Methods: Jervine (JER) 200 mg/kg and JER 400 mg/kg were given orally to the experimental groups 12h after the fasten period. Five minutes later, 25 mg/kg of indomethacin was administered orally to all groups except the healthy and JER 400 mg/kg groups. The experiment was concluded 6 h after the indomethacin. Results: The administration of Jervine at both doses resulted in a significant reduction of the ulcerative area compared to the Indomethacin (INDO). Indomethacin + Jervine 200 mg/kg (INDO + JER + 200 mg/kg) and Indomethacin + Jervine 400 mg/kg (INDO + JER + 400 mg/kg) groups significantly reduced apoptotic cell density compared to INDO group. Biochemically, Jervin decreased the Lipid Peroxidation (MDA) level which increased as a result of indomethacin. Superoxide dismutase (SOD), Catalase (CAT) and Glutathione (GSH) levels, which decreased as a result of indomethacin, were found to increase. Jervine significantly downregulates p53 gene expression compared to the INDO group. Conclusion: In this study, we demonstrated the therapeutic properties of Jervine on ulcers due to its anti-apoptotic and antioxidant regulatory effects. © 2025 The Author(s)eninfo:eu-repo/semantics/openAccessAnti-InflammatoryAntioxidantJervineRatUlcerArticle